Alivus Life Sciences P/E Ratio
Current P/E Ratio
24.65
Moderate Valuation
High - Growth expectations or overvalued
Alivus Life Sciences (ALIVUS) P/E ratio is 24.65 (Moderate), EPS (TTM) ₹45.99, current price ₹1101.20 on NSE — High - Growth expectations or overvalued. See ALIVUS book value to compare market price against book value per share.
Current Valuation Metrics
P/E Ratio
24.65
Current Price
₹1101.20
EPS (TTM)
₹45.99
Exchange
NSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
55.8
Sector Median
31.44
Sector Rank
#11 of 194
Sector Percentile
5.7%
ALIVUS P/E Ratio — Valuation Signal & Historical Context
Alivus Life Sciences P/E 24.65 — signal: Overvalued. For live price, revenue and the complete fundamental profile, see ALIVUS share price.
- Trading at discount to sector average PE of 55.8
ALIVUS vs Healthcare Peers — P/E Ratio Comparison
Alivus Life Sciences P/E 24.65 vs Healthcare average 55.8, median 31.44 — range 2.86–916.67.
Sector Average
55.8
Sector Median
31.44
Lowest P/E
2.86
Highest P/E
916.67
Companies
194
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.61 | ₹64 | Low |
| Sunrest Lifescience | SUNREST | 3.76 | ₹30 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.76 | ₹7,399 | Low |
| Shelter Pharma | SHELTER | 5.23 | ₹47 | Low |
| Dipna Pharmachem | DPL | 5.39 | ₹14 | Low |
| JFL Life Sciences | JFLLIFE | 5.41 | ₹68 | Low |
| Amwill Health Care | AMWILL | 7.26 | ₹83 | Low |
| Zenith Drugs | ZENITHDRUG | 7.69 | ₹84 | Low |
| Galaxy Medicare | GML | 7.8 | ₹27 | Low |